Please login to the form below

Seattle Genetics

This page shows the latest Seattle Genetics news and features for those working in and with pharma, biotech and healthcare.

Seattle Genetics wins FDA priority review for oral HER2 drug

If approved will compete with AZ/Daiichi Sankyo's Enhertu. Seattle Genetics has scored a US Food and Drug Administration priority review for its oral HER2 inhibitor tucatinib in breast cancer, ... Seattle is seeking approval for tucatinib in combination

Latest news

Seattle Genetics makes case for Padcev plus Keytruda in first-line bladder cancer

Seattle Genetics and partner Astellas have reported positive results from an early clinical trial of their antibody drug conjugate Padcev in combination with Merck &Co/MSD’s Keytruda in first-line ... line setting," said Roger Dansey, chief medical
J&J taps TARIS Biomedical for novel bladder cancer technology

However, J&J is not alone in the bladder cancer market. Seattle Genetics and Astellas claimed approval in the US for Padcev (enfortumab vedotin) last week, as a later-line therapy
AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu

In the meantime, further HER2 competition could be coming from Seattle Genetics’ oral drug tucatinib, which recently cleared the phase 3 HER2CLIMB trial as an add-on to Herceptin plus
Seattle, Astellas bag speedy FDA okay for bladder cancer drug

Plans to expand use into earlier bladder cancer treatment. Seattle Genetics and Astellas have claimed approval in the US for Padcev, an antibody-drug conjugate (ADC), as a later-line therapy ... That would drive a sizeable step up in Seattle’s turnover,
EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla

Also on the horizon is Seattle Genetics’ oral HER2 drug tucatinib, which recently cleared the phase 3 HER2CLIMB trial as an add-on to Herceptin plus Roche’s chemotherapy Xeloda (capecitabine) ... Seattle also has ambition to extend tucatinib into

More from news
Approximately 11 fully matching, plus 27 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

Acquisition company. 628. Cascadian Therapeutics/Seattle Genetics. Lead programme tucatinib, oral, small molecule TKI highly selective for HER2 (p2). ... Winding back to last February (DW Issue 80), Immunomedics announced a licensing agreement with
Deal Watch March 2017

In an unusual development, the recent licensing deal between Immunomedics and Seattle Genetics, whereby Seattle Genetics is to pay $250m in cash, up to $1.7bn in milestones, and royalties, has ... sacituzumab govitecan after announcing the deal with
Deal Watch February 2017

Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.
Pharma deals in June 2015

NewCo formation, collaboration. 760. Unum Therapeutics/ Seattle Genetics. Antibody-coupled T-cell receptor technology for 2 antibodies (platform).
Deal Watch table for September 2014

244. Seattle Genetics / Genmab. Licence and collaboration. Additional deal to use Seattle's antibody drug conjugate technology.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

BMS appoints new commercial leader, Davies joins Eisai and more

Prior to this, he served as executive vice president of commercial for Seattle Genetics, where he led all commercial activities for the company.
Douglas Williams named president and CEO of Codiak

These included serving as chief scientific officer and executive vice president of research and development at Seattle Genetics and as senior vice president and Washington site leader at Amgen.
VentiRx appoints James Kyle Bryan as chief medical officer

Dr Bryan joins from Seattle Genetics, where he served as VP, medical affairs and before that as VP of global product development.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Publications director: Competitive salary and bonus scheme

Digital Associate Director - Medcomms: £65000 - £80000 per annum

Account Manager: £Competitive Salary

Account Director, Medical Education: Salary TBC

Account Director, Healthcare Communications: Salary TBC

Brand Manager - Medium Global Pharma Company: £Competitive Financial Package

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Experienced medical editor: Competitive salary and bonus scheme

Scientific Director: £60000 - £85000 per annum, Benefits: Bonus, pension, subsidised gym and much more

Senior External Communications Lead: £Competitive Salary

Account Manager (PR): Great Benefits

Group Director of Medical Affairs and Scientific Strategy, Medic...: Substantial six figure package

Senior Medical Writer, MedComms Agency: Salary TBC

Senior Medical Writer or Lead Medical Writer: £Competitive Salary

Account Director: £Competitive Salary

Account director: Competitive salary and bonus scheme

Subscribe to our email news alerts

PMHub

Add my company

infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Novo Nordisk awakens its ‘Sleeping Beauty’: Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?: Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019: OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...